Alzheimer's Disease
Progressive neurodegenerative disease and the most common cause of dementia. Cannabis has limited evidence for managing behavioral and psychological symptoms of dementia (agitation, sleep disturbance, appetite loss); no evidence demonstrates disease-modifying effects.
- 27 states
- QUALIFYING IN
- Limited
- EVIDENCE
- G30
- ICD-10
Reviewed by Laura H. Meyer
Qualifying states
What it is
Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia, affecting an estimated 6.7 million Americans over age 65. Pathologically, the disease is characterized by amyloid plaques and tau-protein neurofibrillary tangles in the brain. Symptoms include memory loss, language difficulty, executive dysfunction, and (in later stages) behavioral and psychological symptoms of dementia (BPSD) such as agitation, aggression, sleep disturbance, and appetite loss.
Disease-modifying therapies (anti-amyloid antibodies) provide modest benefit at early stages. Most clinical care remains symptomatic.
Cannabis and cannabis-derived therapies
Evidence for cannabis or cannabinoids in Alzheimer's disease is limited and focused on symptomatic management of BPSD rather than disease modification. Small open-label studies have reported improvements in agitation, sleep, and appetite with oral cannabinoids (dronabinol, nabilone). No large randomized controlled trials have demonstrated cognitive benefit, disease-progression delay, or neuroprotective effects.
Alzheimer's disease, dementia, or "agitation of Alzheimer's" is a qualifying condition under several state medical cannabis programs. Caregivers should coordinate use with the patient's geriatric care team given the elevated risk of cognitive side effects and falls in this population.
Frequently asked questions
What does the evidence base say about cannabis for Alzheimer's disease?
Cannabis evidence in Alzheimer's is limited. The 2017 NASEM report did not identify high-tier evidence for cannabis as treatment of Alzheimer's disease. Available studies suggest possible benefit for behavioral and psychological symptoms of dementia (BPSD) (agitation, sleep disturbance, appetite loss) but trials are small and outcomes inconsistent.
Is any cannabis-derived product FDA-approved for Alzheimer's?
No. No cannabis or cannabinoid product is FDA-approved for any indication in Alzheimer's disease. Disease-modifying therapies for early Alzheimer's (anti-amyloid antibodies such as lecanemab and donanemab) are unrelated to cannabis.
Are there practical concerns when older adults with dementia use cannabis?
Yes. Older adults are more susceptible to sedation, orthostatic hypotension, falls, confusion, and drug interactions. Cannabis can interact with anticholinergics, sedatives, and antipsychotics commonly prescribed in dementia care. THC-dominant products can worsen cognition and disorientation. Caregivers and clinicians should weigh symptom-management benefit against fall and cognitive risk.
Does cannabis slow or prevent Alzheimer's progression?
No. There is no clinical evidence that cannabis or cannabinoids slow, prevent, or reverse Alzheimer's disease progression. Any role for cannabis in Alzheimer's care is symptomatic (addressing agitation, sleep, or appetite) not disease-modifying.
Sources
- NIH National Institute on Aging: Alzheimer's Disease Fact Sheetaccessed May 15, 2026
- NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 15, 2026